


# Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA<sub>2</sub>DS<sub>2</sub>-VASc versus CHA<sub>2</sub>DS<sub>2</sub>-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution

Peter Brønnum Nielsen<sup>1,2</sup> Thure Filskov Overvad<sup>2,3</sup> 

<sup>1</sup>Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark

<sup>2</sup>Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark

<sup>3</sup>Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

Address for correspondence Peter Brønnum Nielsen, MPH, PhD, Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark (e-mail: pbn@rn.dk).

Thromb Haemost 2020;120:894–898.

## Abstract

Stroke prevention is a key clinical concern in the management of patients with atrial fibrillation. Oral anticoagulation treatment reduces the risk of disabling stroke, but the treatment increases the risk of bleeding. For decades, the decision to initiate oral anticoagulation has been guided by clinical risk scoring systems such as the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores. In this narrative review, we focus on the recent discussion of the “Sc” (Sex Category) criterion in the CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Epidemiological considerations when assessing stroke rates in cohorts are discussed, and the implications of different methodological approaches are outlined. Next, we review studies investigating the association of the “Sc” criterion on the stroke rates under various approaches. Lastly, we discuss potential consequences of implementing the recently suggested sex-less CHA<sub>2</sub>DS<sub>2</sub>-VA score, which leaves out female sex from stroke risk assessment in atrial fibrillation.

## Keywords

- ▶ stroke/prevention
- ▶ cardiology
- ▶ epidemiological studies

## Stroke Risk in Atrial Fibrillation

Stroke prevention is a key clinical concern when patients present with atrial fibrillation (AF), and appropriate risk stratification is needed to balance the benefit of thromboprophylaxis against the risk of bleeding.<sup>1,2</sup> For more than three decades, scientific evidence has accumulated to show that oral anticoagulant treatment effectively reduces the risk of stroke. Importantly, these observations are consistent across broad and heterogeneous populations of AF patients, including subgroups of age, sex, cardiovascular comorbidities, and cancer.<sup>3,4</sup>

Historically, the CHADS<sub>2</sub> score was derived to allow for predicting the risk of stroke among patients presenting with AF.<sup>5</sup> However, a significant proportion of the patients were classified as being at “intermediate” risk of stroke for who anticoagulation recommendations were unclear, and there-

fore less helpful for guiding the clinicians in the dichotomous decision to initiate oral anticoagulant treatment or not. A refinement was later proposed and validated the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, which had the strength of better classifying patients at “truly low risk,” meaning that the score identified a group of patients who were unlikely to benefit from oral anticoagulant treatment. A recent independent Patient-Centered Outcomes Research Institute systematic review suggested that the CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, and ABC scores had the best predictive performance for stroke events in terms of c-statistics.<sup>6</sup> Guidelines have gradually changed recommendations on which patients who should receive stroke prevention with oral anticoagulant treatment based on presence of the number of risk factor included in the CHA<sub>2</sub>DS<sub>2</sub>-VASc score.

The very purpose of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score is to be sufficiently reductionist, which enables it to be used as a

received

February 21, 2020

accepted after revision

March 17, 2020

© 2020 Georg Thieme Verlag KG  
Stuttgart · New York

DOI <https://doi.org/10.1055/s-0040-1710014>.  
ISSN 0340-6245.

checklist in everyday clinical practice. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score, which includes female sex as a risk component (sex category: female), was formally implemented for clinical stroke risk stratification in European guidelines in 2010, and this score is currently the preferred risk score in most major international guidelines, which recommend (or at least consider) oral anticoagulation to men with a score  $\geq 1$  and women with a score  $\geq 2$ .<sup>7-10</sup>

Recently, scientific focus has shifted toward the “sex category (Sc)” criterion with the objective to examine at what score level the 1 point off-set should have clinical implications (i.e. treatment recommendations). In fact, the latest Australian guidelines have recently recommended use of a CHA<sub>2</sub>DS<sub>2</sub>-VA score deliberately leaving out the female sex criterion from the score.<sup>11</sup>

### Epidemiological Considerations When Investigating the “Sex Category” Criterion

In the attempt to investigate the risk of stroke in AF with the intention to make inference about preventive strategies, it is essential to construct a cohort free from oral anticoagulant treatment.

Various methodological considerations and epidemiological choices have been shown to affect the assessment of associated stroke risks (or more commonly, stroke rates), including use of a blanking period to avoid very short individual follow-up times,<sup>12</sup> where AF is diagnosed simultaneously with a stroke event; defining at-risk follow-up time free from oral anticoagulant treatment<sup>13</sup>; and source population with careful consideration of factors, such as different ethnic origin, coding practice and validity, and hospital-based cohorts versus primary care-based cohorts, etc.<sup>14-17</sup> Also, methodological issues need scrutiny, especially where observational cohorts were confined to AF patients who were never ever started on oral anticoagulation, thus “conditioning on the future” and biasing toward lower event rates.<sup>18</sup> Similarly, some cohorts report only baseline anticoagulation status, with no assessment of change in anticoagulation use during follow-up anticoagulation.<sup>19</sup> Indeed, censoring for anticoagulation initiation at follow-up is one appropriate methodology for some investigations; the overall message is that anticoagulant treatment as a yes/no adjustment on multivariate analysis is not an adequate approach to account for the effect of oral anticoagulant treatment on stroke risk.<sup>13</sup>

It is well known that individual risk factor components in the CHA<sub>2</sub>DS<sub>2</sub>-VASc score do not carry equal weights.<sup>20</sup> Also, risk factor prevalence change over time reflecting the dynamic nature of risk rather than being a static “one off” assessment at baseline to predict stroke risk many years later.<sup>21,22</sup> Indeed, clinical risk scores (and the CHA<sub>2</sub>DS<sub>2</sub>-VASc score is no exception) have only modest predictive value for identifying high-risk patients that sustain events and should not be overinterpreted given they are mere simplifications of assessing risk.

Therefore, investigators may be interested in examining the contribution of individual diseases in terms of stroke risk factor(s) to ascertain whether or not these differ among

females and males. Nevertheless, guidelines recommend assessing stroke risk based only on score point levels, regardless of which risk components (age, heart failure, diabetes, etc.) that contribute to the specific score level. While this distinction may seem trivial, it is central when investigating associated stroke risk. Making inference about difference in stroke risk in females versus males with 1 point on the CHA<sub>2</sub>DS<sub>2</sub>-VA(Sc) score is not equivalent to investigating the difference in stroke rates in females and males with (e.g.) hypertension and no other prevalent risk factors. Similarly, there is an interpretational difference in comparing a female with a score level of 3 with a male at same score level, than when comparing a female aged 68 (1 point) with heart failure (1 point) and hypertension (1 point) with a male peer with the exact same risk factor profile. In other words, creating a model including individual components from the score, that is, the disease rather than the score point level does not allow for inference on score level. Essentially, what is performed is an investigation of differences in associated stroke risk according to sex when holding other components (diseases) constant. While this approach has scientific advantages, it also has major limitations regarding the interpretation on how the score functions and translates into use in clinical practice.

### Stroke Rate Contribution from the “Sex Category” Criterion

Observations of a higher incidence of stroke in women compared with men in the setting of atrial fibrillation date back also to before the introduction of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>23-25</sup> Women do carry an overall higher risk of thromboembolism, but the sex-specific differences in stroke risk vary across CHA<sub>2</sub>DS<sub>2</sub>-VASc score levels.<sup>26</sup>

However, in an analysis of the J-RHYTHM Registry, an excess risk in females versus males was not observed.<sup>27</sup> Notwithstanding that this registry cohort consisted of a selected proportion of AF patients opting in for the study (and therefore may have limited generalizability), the methodological approach to reach their conclusion may be questioned. Although some data were presented as rates, it appears that the data were not time to event but rather binary outcomes with no information on time per subject. Indeed, the relative measure provided was odds ratio (OR), thus hampering comparison with other studies in this field, which traditionally have used longitudinal data with information on at-risk time to report relative measures based on incidence rates. In the Japanese study, a multivariable logistic regression approach was applied to reach the conclusion that female sex was not a risk factor for thromboembolism when adjusting for various risk factors and treatment. As mentioned, such an approach may be of scientific interest, but the applicability into clinical practice on stroke risk assessment based on score points in AF is lacking.

In a large Swedish cohort of unselected AF patients, Tomasdotir et al showed that associated stroke rates were different when using a point-based approach than when using a disease-specific risk factors approach stratified

according to sex.<sup>28</sup> They argued that the excess stroke risk observed among females was score level dependent, but this itself does not allow inference on the magnitude of excess risk that female sex contributes within each level of the score.

A large Danish cohort study of nonanticoagulated patients with AF reported overall higher risks of stroke in women, but when stratified by CHA<sub>2</sub>DS<sub>2</sub>-VASc score levels, the higher risk for females was only evident among those with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores  $\geq 2$ .<sup>29</sup> What this study added was the specific contribution from the “Sc” criterion as a difference per stratified score level. This allowed for inference on the magnitude of the risk-differences due to sex across score levels (i.e. effect modification). The risk ratios from the model including the interaction term between sex (males as reference) and score level showed that females were consistently at higher risk of stroke at score levels at 1 or higher (–Fig. 1).

### Potential Clinical Consequences of Changing the Risk Score

Some studies support the existence of a sex-specific stroke risk variation according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score levels.<sup>28,30</sup> These observations have led to the implementation of the CHA<sub>2</sub>DS<sub>2</sub>-VA score as the preferred stroke risk score for guiding anticoagulation decisions in patients with AF in the recent guidelines from Australia and New Zealand,<sup>31</sup> despite the lack of any comparative formal risk score validation. Although tempting, the manoeuvre of completely ignoring the well-established sex-differences in stroke risk may have deleterious consequences.<sup>32</sup>


First, an overall underuse of oral anticoagulation across all levels of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score has been repeatedly reported,

the reasons for which are not entirely understood.<sup>33,34</sup> Second, women do carry an overall higher risk of stroke than their male counterparts, and thus the greatest benefit in terms of absolute stroke risk reduction is among women. Several reports of sex-differences in oral anticoagulation use have indicated that underuse and nonadherence is most frequent among women.

A comprehensive report from 2017 based on the American PINNACLE National Cardiovascular Data Registry demonstrated that women were less likely than men to receive oral anticoagulation across all CHA<sub>2</sub>DS<sub>2</sub>-VASc score levels.<sup>35</sup> According to guidelines, female sex is not associated with bleeding once oral anticoagulation is initiated; therefore, reluctance to prescribe anticoagulation due to bleeding risk is an unlikely explanation for this consistent pattern of underuse.<sup>10</sup> More recently, a Tasmanian report also demonstrated a higher degree of the underuse of oral anticoagulation among women than men with AF and a guideline-recommended indication for oral anticoagulation, with an adjusted OR of 0.83 (95% confidence interval [CI]: 0.69–0.99).<sup>36</sup> Another sizeable contemporary American report using Medicare data found female sex to be a negative predictor of initiation of oral anticoagulation in AF with an OR of 0.59 (95% CI: 0.55–0.64).<sup>37</sup>

Once anticoagulation is prescribed, adherence, and persistence to treatment is fundamental for optimal stroke prevention.<sup>38,39</sup> A Dutch study recently found that 34% of patients with newly diagnosed AF had stopped treatment with nonvitamin K antagonists after one year, with female sex being associated with a higher risk of nonadherence.<sup>40</sup>

In summary, women are more likely than men to receive suboptimal anticoagulation, a difference not likely to be explained by differences in bleeding risk profiles. If the Sc



**Fig. 1** Graph illustrating the risk of thromboembolism for each score level point for males and females. The dotted line reflects the contribution from the (sex category) criterion as an interaction term. Reproduced from Nielsen et al.<sup>29</sup>

(sex category) component is removed from the CHA<sub>2</sub>DS<sub>2</sub>-VASC score, we take away the possibility that patients and their treating physicians can weigh in the patient's sex when balancing the expected benefits and harms from oral anticoagulation.<sup>41</sup> Ultimately, this could worsen the established pattern of treatment underuse in women with AF. Future studies may confirm that there are valid reasons causing that women receive oral anticoagulation less frequently than men, but until such data exist, a continued need for focus on sex-differences in stroke risk in AF is preferable.

#### Conflict of Interest

P.B.N. has received speaking fees from Boehringer Ingelheim, consulting fees from Bayer and Daiichi-Sankyo, and grant support from Bristol-Myers Squibb/Pfizer and Daiichi-Sankyo. T.F.O. declared no conflict of interest.

#### References

- Proietti M, Mujovic N, Potpara TS. Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision. *Thromb Haemost* 2018;118(12):2014–2017
- Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. *Thromb Haemost* 2017;117(07):1230–1239
- Lega J-C, Bertolotti L, Gremillet C, et al. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. *PLoS One* 2014;9(03):e91398
- Delluc A, Wang TF, Yap ES, et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH. *J Thromb Haemost* 2019;17(08):1247–1252
- Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;285(22):2864–2870
- Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. *Thromb Haemost* 2018;118(12):2171–2187
- Chiang C-E, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. *J Arrhythm* 2017;33(04):345–367
- Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. *Chest* 2018;154(05):1121–1201
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. *J Am Coll Cardiol* 2019;74(01):104–132
- Kirchhof P, Benussi S, Kotecha D, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;37(38):2893–2962
- Brieger D, Amerena J, Attia J, et al. National Heart foundation of australia and the cardiac society of australia and new zealand: australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. *Heart Lung Circ* 2018;27(10):1209–1266
- Allan V, Banerjee A, Shah AD, et al. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. *Heart* 2017;103(03):210–218
- Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. *Sci Rep* 2016;6:27410
- Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. *Circulation* 2017;135(03):208–219
- Nielsen PB, Lip GYH. Adding rigor to stroke rate investigations in patients with atrial fibrillation. *Circulation* 2017;135(03):220–223
- Nielsen PB, Chao T-F. The risks of risk scores for stroke risk assessment in atrial fibrillation. *Thromb Haemost* 2015;113(06):1170–1173
- Heidbuchel H. The search for the tipping point on when to anticoagulate patients with atrial fibrillation. *Heart* 2017;103(03):181–183
- Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA<sub>2</sub>DS<sub>2</sub>-VASC score of 1. *J Am Coll Cardiol* 2015;65(03):225–232
- Maeda T, Nishi T, Funakoshi S, et al. Risks of bleeding and stroke based on CHA<sub>2</sub>DS<sub>2</sub>-VASC scores in Japanese patients with atrial fibrillation: a large-scale observational study using real-world data. *J Am Heart Assoc* 2020;9(05):e014574
- Nielsen PB, Larsen TB, Lip GYH. Misconceptions on interpretation of risk prediction tools in atrial fibrillation. *Am J Med* 2016;129(05):e31
- Yoon M, Yang PS, Jang E, et al. Dynamic changes of CHA<sub>2</sub>DS<sub>2</sub>-VASC score and the risk of ischaemic stroke in asian patients with atrial fibrillation: a nationwide cohort study. *Thromb Haemost* 2018;118(07):1296–1304
- Chao TF, Liao JN, Tuan TC, et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA<sub>2</sub>DS<sub>2</sub>-VASC score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially 'low-risk' patients. *Thromb Haemost* 2019;119(07):1162–1170
- Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA* 2003;290(08):1049–1056
- Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. *Neurology* 2007;69(06):546–554
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137(02):263–272
- Marzona I, Proietti M, Farcomeni A, et al. Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: a systematic review and meta-analysis of 993,600 patients. *Int J Cardiol* 2018;269:182–191
- Inoue H, Atarashi H, Okumura K, et al; J-RHYTHM Registry Investigators. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. *Am J Cardiol* 2014;113(06):957–962
- Tomasdottir M, Friberg L, Hijazi Z, Lindbäck J, Oldgren J. Risk of ischemic stroke and utility of CHA<sub>2</sub>DS<sub>2</sub>-VASC score in women and men with atrial fibrillation. *Clin Cardiol* 2019;42(10):1003–1009
- Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA<sub>2</sub>DS<sub>2</sub>-VA score rather than CHA<sub>2</sub>DS<sub>2</sub>-VASC? *Circulation* 2018;137(08):832–840
- Tomita H, Okumura K, Inoue H, et al; J-RHYTHM Registry Investigators. Validation of risk scoring system excluding female sex from CHA<sub>2</sub>DS<sub>2</sub>-VASC in Japanese patients with nonvalvular atrial fibrillation – subanalysis of the J-RHYTHM registry. *Circ J* 2015;79(08):1719–1726
- Brieger D, Amerena J, Attia J, et al; NHFA CSANZ Atrial Fibrillation Guideline Working Group. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. *Heart Lung Circ* 2018;27(10):1209–1266

- 32 Linde C, Bongiorni MG, Birgersdotter-Green U, et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. *Europace* 2018;20(10):1565–1565a0
- 33 Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. *Am J Med* 2010;123(07):638–645.e4
- 34 Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. *JAMA Cardiol* 2016;1(01):55–62
- 35 Thompson LE, Maddox TM, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. *J Am Heart Assoc* 2017;6(07):pii: e005801
- 36 Pilcher SM, Alamneh EA, Chalmers L, Bereznicki LR. The Tasmanian Atrial Fibrillation Study (TAFS): differences in stroke prevention according to sex. *Ann Pharmacother* 2020: 1060028020904969
- 37 Essien UR, Magnani JW, Chen N, Gellad WF, Fine MJ, Hernandez I. Race/ethnicity and sex-related differences in direct oral anticoagulant initiation in newly diagnosed atrial fibrillation: a retrospective study of medicare data. *J Natl Med Assoc* 2020;112(01): 103–108
- 38 Hylek EM. Treatment persistence in atrial fibrillation: the next major hurdle. *Thromb Haemost* 2018;118(12):2018–2019
- 39 Pritchett RV, Bem D, Turner GM, et al. Improving the prescription of oral anticoagulants in atrial fibrillation: a systematic review. *Thromb Haemost* 2019;119(02):294–307
- 40 Zielinski GD, van Rein N, Teichert M, et al. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. *Res Pract Thromb Haemost* 2019;4(01):141–153
- 41 Overvad TF, Potpara TS, Nielsen PB. Stroke Risk Stratification: CHA<sub>2</sub>DS<sub>2</sub>-VA or CHA<sub>2</sub>DS<sub>2</sub>-VASc? *Heart Lung Circ* 2019;28(02): e14–e15